{
    "organizations": [],
    "uuid": "a217bdc92cdaf4c9d04ce95660a1c21b8d38501b",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-neovacs-raises-1-million-euros-in/brief-neovacs-raises-1-million-euros-in-private-placement-and-3-8-million-euros-by-issue-of-convertible-bonds-idUSFWN1QI1H0",
    "ord_in_thread": 0,
    "title": "BRIEF-Neovacs Raises 1 Million Euros In Private Placement And 3.8 Million Euros By Issue Of Convertible Bonds‍​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 28 (Reuters) - NEOVACS SA:\n* RAISES EUR 1 MILLION IN PRIVATE PLACEMENT AND EUR 3.8 MILLION IN CONVERTIBLE BONDS ISSUE‍​\n* CONVERTIBLE BONDS’ MATURITY DATE FEB 26, 2020‍​\n* BONDS SUBSCRIBED BY 3 EUROPEAN INVESTORS, PRIVATE PLACEMENT SUBSCRIBED BY 2 FRENCH INSTITUTIONAL INVESTORS\n* PHASE IIB CLINICAL TRIAL OF IFNA KINOIDE LUPUS TREATMENT EXPECTED IN JUNE 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-03-01T01:12:00.000+02:00",
    "crawled": "2018-03-01T21:10:53.041+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "neovacs",
        "sa",
        "raise",
        "eur",
        "million",
        "private",
        "placement",
        "eur",
        "million",
        "convertible",
        "bond",
        "convertible",
        "bond",
        "maturity",
        "date",
        "feb",
        "bond",
        "subscribed",
        "european",
        "investor",
        "private",
        "placement",
        "subscribed",
        "french",
        "institutional",
        "investor",
        "phase",
        "iib",
        "clinical",
        "trial",
        "ifna",
        "kinoide",
        "lupus",
        "treatment",
        "expected",
        "june",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}